Stefan Zajic

1.0k total citations
37 papers, 735 citations indexed

About

Stefan Zajic is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Stefan Zajic has authored 37 papers receiving a total of 735 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 9 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Stefan Zajic's work include CAR-T cell therapy research (9 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Immunotherapy and Immune Responses (8 papers). Stefan Zajic is often cited by papers focused on CAR-T cell therapy research (9 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Immunotherapy and Immune Responses (8 papers). Stefan Zajic collaborates with scholars based in United States, United Kingdom and Russia. Stefan Zajic's co-authors include Greg M. Thurber, K. Dane Wittrup, S. Aubrey Stoch, Julie A. Stone, JA Wagner, Nick D. Hutson, Ralph T. Yang, Deborah Panebianco, Keith Gottesdiener and Raymond Evers and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Stefan Zajic

34 papers receiving 715 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefan Zajic United States 12 376 306 157 101 96 37 735
Jenny Zheng United States 13 315 0.8× 143 0.5× 72 0.5× 61 0.6× 96 1.0× 26 634
Rajul K. Jain United States 16 482 1.3× 222 0.7× 79 0.5× 55 0.5× 24 0.3× 45 931
E H Cooper United Kingdom 20 523 1.4× 310 1.0× 55 0.4× 98 1.0× 12 0.1× 39 1.2k
Takeshi Masuda Japan 15 140 0.4× 239 0.8× 28 0.2× 21 0.2× 61 0.6× 40 862
Jesús Martín Spain 15 148 0.4× 254 0.8× 14 0.1× 16 0.2× 21 0.2× 41 939
Alice Zoccoli Italy 19 336 0.9× 306 1.0× 15 0.1× 94 0.9× 16 0.2× 34 956
E. J. Freireich United States 22 512 1.4× 297 1.0× 24 0.2× 64 0.6× 23 0.2× 66 1.6k
Dirk Lebrecht Germany 21 217 0.6× 388 1.3× 17 0.1× 40 0.4× 18 0.2× 32 1.4k
Isaac Mizrahi United States 12 243 0.6× 287 0.9× 212 1.4× 38 0.4× 6 0.1× 22 1.2k
Yuping Gong China 20 231 0.6× 669 2.2× 22 0.1× 19 0.2× 23 0.2× 83 1.2k

Countries citing papers authored by Stefan Zajic

Since Specialization
Citations

This map shows the geographic impact of Stefan Zajic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Zajic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Zajic more than expected).

Fields of papers citing papers by Stefan Zajic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Zajic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Zajic. The network helps show where Stefan Zajic may publish in the future.

Co-authorship network of co-authors of Stefan Zajic

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Zajic. A scholar is included among the top collaborators of Stefan Zajic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Zajic. Stefan Zajic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
D’Angelo, Sandra P., Mihaela Druta, Brian A. Van Tine, et al.. (2025). Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma. Journal of Clinical Oncology. 43(15). 1777–1788. 8 indexed citations
2.
Samant, Tanay S., Herbert Struemper, Morris Muliaditan, et al.. (2024). P4.11E.28 Pharmacological Comparison of Dostarlimab and Pembrolizumab in Metastatic Non-Small Cell Lung Cancer in PERLA. Journal of Thoracic Oncology. 19(10). S407–S408.
3.
Kusic, Dara, Stefan Zajic, Neda Gharani, et al.. (2023). Genome-wide Association Study of Caffeine Consumption Using Coriell Personalized Medicine Collaborative Data. 5(1). 1 indexed citations
4.
Demin, Oleg, et al.. (2023). 338 Comparison of lymphodepleting chemotherapy regimens as preconditioning for T-cell therapies. SHILAP Revista de lepidopterología. A387–A387. 2 indexed citations
5.
6.
Akce, Mehmet, Anthony B. El-Khoueiry, Sarina A. Piha‐Paul, et al.. (2021). Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. Cancer Chemotherapy and Pharmacology. 88(5). 825–836. 11 indexed citations
7.
D’Angelo, Sandra P., Mihaela Druta, Brian Andrew Van Tine, et al.. (2021). Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.. Journal of Clinical Oncology. 39(15_suppl). 11521–11521. 7 indexed citations
8.
Zajic, Stefan, et al.. (2020). A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor. Journal of Pharmacokinetics and Pharmacodynamics. 47(5). 473–484. 1 indexed citations
9.
Yee, Ka Lai, Huub Jan Kleijn, Stefan Zajic, Marcus Dörr, & Rebecca E. Wrishko. (2020). A time-to-event analysis of the exposure–response relationship for bezlotoxumab concentrations and CDI recurrence. Journal of Pharmacokinetics and Pharmacodynamics. 47(2). 121–130. 3 indexed citations
10.
Zajic, Stefan, Joseph P. Jarvis, Pan Zhang, et al.. (2018). Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative. Pharmacogenetics and Genomics. 29(3). 49–57. 10 indexed citations
11.
Chen, Xia, Ji Jiang, Pei Hu, et al.. (2018). Odanacatib Pharmacokinetics Comparison Between Chinese and Non‐Chinese Postmenopausal Women. Clinical Pharmacology in Drug Development. 7(7). 744–750. 4 indexed citations
12.
Zajic, Stefan, Stefaan Rossenu, David Hreniuk, et al.. (2016). The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women. Drug Metabolism and Disposition. 44(9). 1450–1458. 6 indexed citations
13.
Wright, D. Hamish, Kevin Brown, Geng‐Chang Yeh, et al.. (2015). Bioequivalence of Alendronate and Vitamin D3 in a Combination Tablet Versus Corresponding-Dose Individual Tablets in Healthy Taiwanese Volunteers, Determined Using a Novel Plasma Alendronate Assay. Current Therapeutic Research. 77. 116–121. 1 indexed citations
14.
Chow, Andrew, Justin Earp, Manish Gupta, et al.. (2013). Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions. The Journal of Clinical Pharmacology. 54(5). 593–601. 11 indexed citations
15.
C, Liu, et al.. (2013). Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin.. PubMed. 20(3). e312–20. 7 indexed citations
16.
Stoch, S. Aubrey, David Hreniuk, Chengcheng Liu, et al.. (2013). Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration. International Journal of Clinical Pharmacology and Therapeutics. 51(8). 688–692. 7 indexed citations
17.
Reitman, Marc L., Xiaoyan Chu, Xiaoxin Cai, et al.. (2010). Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design. Clinical Pharmacology & Therapeutics. 89(2). 234–242. 133 indexed citations
18.
Schwartz, Jules I., Mark Stroh, Bing Gao, et al.. (2009). Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone. Cardiovascular Therapeutics. 27(4). 239–245. 4 indexed citations
19.
Stoch, S. Aubrey, Stefan Zajic, Julie A. Stone, et al.. (2009). Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies. Clinical Pharmacology & Therapeutics. 86(2). 175–182. 124 indexed citations
20.
Churchill, Stuart W. & Stefan Zajic. (2002). Prediction of fully developed turbulent convection with minimal explicit empiricism. AIChE Journal. 48(5). 927–940. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jenny Zheng Breakdown of academic impact, for papers by Rajul K. Jain Breakdown of academic impact, for papers by E H Cooper Breakdown of academic impact, for papers by Takeshi Masuda Breakdown of academic impact, for papers by Jesús Martín Breakdown of academic impact, for papers by Alice Zoccoli Breakdown of academic impact, for papers by E. J. Freireich Breakdown of academic impact, for papers by Dirk Lebrecht Breakdown of academic impact, for papers by Isaac Mizrahi Breakdown of academic impact, for papers by Yuping Gong
Rankless by CCL
2026